Premium
Clinical evaluation of fructose‐1,6‐bisphosphate for in situ cold perfusion in hepatic resection
Author(s) -
Nakai Takehiro,
Tanimura Hiroshi,
Taniguchi Katsutoshi,
Mori Kazunari,
Yamoto Hideki
Publication year - 1995
Publication title -
journal of hepato‐biliary‐pancreatic surgery
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.63
H-Index - 60
eISSN - 1868-6982
pISSN - 0944-1166
DOI - 10.1007/bf02348743
Subject(s) - perfusion , medicine , hepatectomy , hepatocellular carcinoma , bilirubin , fructose , resection , in situ , surgery , energy charge , anesthesia , urology , chemistry , biochemistry , organic chemistry , receptor , adenylate kinase
In situ cold perfusion was employed in two patients with large hepatocellular carcinoma. Fructose‐1,6‐bisphosphate, a cytoprotective drug, was added to the oxygenated perfusate, resulting in reduction of the liver injury that occurs during liver perfusion and allowing hepatic resection to proceed safely. Recovery after, reperfusion of the energy charge in the hepatic tissue sampled during surgery was good in both patients. During the postoperative course, serum GOT and GPT values in the two patients were normalized 7–13 days postoperatively after a peak on the 1st and 2nd postoperative days, respectively. This finding was similar to the usual course after hepatectomy. Serum total bilirubin gradually decreased from the peak 2.3 mg/dl on the 5th postoperative day in case 1, and from 3.6 mg/dl on the 7th postoperative day in case 2. There were no serious complications in either patient.